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RESPONSE TO DAVID NACE AND PAUL DRINKA
To the Editor: We appreciate the thoughtful comments of
Drs. Nace and Drinka concerning our article.1,2 They
highlighted our definitions of clinical and strict urinary
tract infection (UTI) and concluded that, by using the clin-
ical definition, it is not possible to infer any benefit from
cranberry capsules in the prevention of UTI.
We agree that, for many studies, the appropriate crite-
rion standard for diagnosing UTI is detection of the patho-
gen in the presence of clinical symptoms. A less-rigorous
definition can easily lead to overdiagnosis and false conclu-
sions, but residents in long-term care facilities (LTCF) are
a vulnerable population, mostly with severe cognitive
impairment, multiple chronic comorbidities, functional dis-
abilities, and urinary incontinence. Signs and symptoms of
UTI are frequently absent,3 and differentiating asymptom-
atic from symptomatic UTI in older persons with dementia
is difficult and challenging.4,5 The use of the criterion stan-
dard for diagnosing UTI is not suitable for LTCF residents
and would lead to substantial underdiagnosis. As a result,
there is no criterion standard in diagnosing UTI in LTCF
populations, and most clinical criteria to ascertain UTI in
LTCF residents are based on consensus.6–8
To make research in real-world LTCF populations pos-
sible, we have chosen a clinical UTI definition. Our clinical
definition is a broad and practical definition, following clin-
ical practice guidelines for LTCF residents9,10 and based on
the experience of the elderly care physician and nursing
staff, which is consistent with a previous study.5 Experi-
enced staff can achieve even better diagnostic precision
than urine culture.11 There is also recent evidence that mic-
turition-related signs and symptoms are predictive of UTI.4
Although our clinical definition is different from the strict
definition, it closely reflects clinical care in LTCF and adds
knowledge to practice guidelines to assist physicians in
making decisions. Moreover, our cost-effectiveness analysis
showed the relevance of our clinical definition, because
clinical UTIs were followed by a significant deterioration in
quality of life, survival, care dependency, and costs.12
Our study concludes that, for elderly LTCF residents
with high UTI risk, taking cranberry capsules twice daily
results in a lower incidence of clinical UTI. In daily prac-
tice, prevention with cranberry will also reduce antibiotic
prescription, including inappropriate prescriptions.
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REVIEWING THE SAFETY OF LORATADINE FOR
ELDERLY ADULTS: A POTENTIAL SHORTCOMING
OF THE 2012 BEERS CRITERIA
To the Editor: Anticholinergic drugs produce a variety of
adverse effects, including dry mouth and eyes, constipa-
tion, blurred vision, rapid heart rate, dizziness, sedation,
confusion, delirium, hallucinations, and cognitive impair-
ment.1,2 Furthermore, anticholinergic toxicity has been
reported as a common problem in elderly adults, and anti-
cholinergic drug use is closely associated with serious neg-
ative outcomes in this population, such as risk of falls,
behavioral symptoms (including agitation), and high mor-
tality.1,2 Anticholinergic drugs are often mentioned in
explicit criteria for inappropriate medication use in older
adults, such as the Beers criteria.1,3 In 2012, the American
Geriatrics Society revised these criteria and included lorat-
adine on the list of potentially inappropriate medication
for elderly adults owing to its strong anticholinergic prop-
erties; these drugs were to be avoided in cases of lower uri-
nary tract symptoms, benign prostatic hyperplasia, chronic
constipation, and cognitive impairment and delirium.3
Loratadine is a second-generation H1 antihistamine, as
are levocabastine, azelastine, bilastine, desloratadine, ebas-
tine, cetirizine, fexofenadine, levocetirizine, and rupatadine;
the characteristics of second-generation H1 antihistamines
make them more effective and safer than first-generation H1
antihistamines (e.g., diphenhydramine, hydroxyzine, pro-
methazine, clemastine, triprolidine). Moreover, first-genera-
tion H1 antihistamines are associated with undesirable
sedation and anticholinergic side effects.4–6 Under the
umbrella term “sedation” is a range of conditions including
somnolence, impaired concentration, and poor learning abil-
ity.5 Central nervous system (CNS) and cardiac toxicity have
been the most serious adverse effects associated with H1
antihistamines. Cardiac toxicity is rare but is of considerable
concern because of the associated risk of death. CNS toxicity
produced by first-generation H1 antihistamines is wide-
spread, but even during the years when first-generation H1
antihistamines were widely used, case reports of cardiac tox-
icity were uncommon, and epidemiological studies involving
large sample sizes identified only a few cases of H1 antihista-
mine–associated ventricular arrhythmias.7 Thereafter, sev-
eral second-generation H1 antihistamines, the use of which
was devoid of any associated cardiac toxicity and significant
CNS toxicity,5,7 became the H1 antihistamines of choice.7
Loratadine is considered a nonsedating antihistamine.
At recommended doses (10 mg/d), no significant differences
between loratadine and placebo for any measure of cogni-
tive or psychomotor performance, mood, or sedation were
observed.5,6 In contrast, other performance studies that used
higher doses of loratadine (20 and 40 mg) showed signifi-
cant performance impairment and sedation in some tests
(e.g., choice reaction time, adaptive tracking, digit-symbol
substitution) in comparison with placebo.5 In light of the
evidence demonstrating its safety, the inclusion of loratadine
in the list of potentially inappropriate medications solely on
the basis of the studies that the 2012 revised Beers criteria
reference is not justified. Those three studies, which the
American Geriatrics Society cited,8–10 do not provide any
evidence of loratadine being an antihistamine with strong
anticholinergic properties. One of these studies9 gave lorata-
dine 2 points on the Anticholinergic Risk Scale, indicating
that it entails intermediate risk; another study8 gave lorata-
dine 0 points, which means that it has no known anticholin-
ergic properties. Moreover, a recent systematic review of
anticholinergic risk scales in older adults1 did not mention
that loratadine has strong anticholinergic properties or the
potential for serious adverse effects in elderly adults. That
review1 cited two of the three studies that the 2012 Beers
criteria referenced;8,9 the third study,10 also used as a refer-
ence by the American Geriatrics Society, was not included in
the systematic review, probably because it was a narrative
review that did not provide any evidence of loratadine pos-
sessing strong anticholinergic properties.
That review1 has great clinical implications because the
summarized studies describe different drugs with anticholin-
ergic properties. Although this study was not a systematic
review of randomized clinical trials, the data can be applied
to clinical practice. The findings of this review provide
insights into a broad issue that could have not been
addressed through clinical trials. The finding that loratadine
is safe for elderly adults is of great consequence to health
professionals concerned with providing treatment for people
of this age group. In addition, it highlights a probable short-
coming of the Beers criteria, which are currently used as a
basis for supporting prescription for elderly adults.3
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